Finanzen von Harmony Biosciences Holdings Inc (HRMY)HRMYHarmony Biosciences Holdings Inc

Evaluating the bottom line, Harmony Biosciences Holdings, Inc. maintains a gross margin of 75.81%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 34.18%, while the net margin is 28.87%. These profitability ratios, combined with a Return on Equity (ROE) of 20.46%, provide a clear picture of how effectively HRMY converts its operational activities into shareholder value.

In the context of the broader market, HRMY competes directly with industry leaders such as OCUL and BHVN. With a market capitalization of $2.40B, it holds a leading position in the sector. When comparing efficiency, HRMY's gross margin of 75.81% stands against OCUL's 85.08% and BHVN's N/A. Such benchmarking helps identify whether Harmony Biosciences Holdings, Inc. is trading at a premium or discount relative to its financial performance.

Harmony Biosciences has demonstrated robust financial performance, with a gross margin of 75.81% in Q2 2026 and a net income of $75.43 million, showcasing strong profitability and operational efficiency.